Fischer Andre
Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Grisebachstr. 5, 37077 Göttingen, Germany; Research Group for Epigenetic Mechansims of Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Göttingen, Grisebachstr. 5, 37077 Göttingen, Germany.
Neuropharmacology. 2014 May;80:95-102. doi: 10.1016/j.neuropharm.2014.01.038. Epub 2014 Jan 31.
Alzheimer' s disease (AD) is the most common form of dementia causing an increasing emotional and economical burden to our societies. Although much progress has been made regarding the molecular mechanisms that underlie AD pathogenesis effective therapies are not available yet. The emerging field of neuroepigenetics has provided evidence that de-regulation of epigenetic processes play a role in AD. In this article we will critically review the primary research data that led to the hypothesis that targeting histone-modifying enzymes could be used to treat AD pathogenesis and address the question if the field is ready to translate such findings into clinical application.
阿尔茨海默病（AD）是痴呆最常见的形式，给我们的社会带来日益沉重的情感和经济负担。尽管在AD发病机制的分子机制方面已经取得了很大进展，但尚未有有效的治疗方法。新兴的神经表观遗传学领域已提供证据表明，表观遗传过程的失调在AD中起作用。在本文中，我们将批判性地回顾导致以下假设的主要研究数据：靶向组蛋白修饰酶可用于治疗AD发病机制，并探讨该领域是否已准备好将这些发现转化为临床应用。
